Immune profiling of the macroenvironment in colorectal cancer unveils systemic dysfunction and plasticity of immune cells

Abstract

	•Distinct immunotypes are identified in the CRC macroenvironment.
	•TLS and immunotherapy exert influence on the immune macroenvironment.
	•TLS presence correlates with patient survival, CMS and therapeutic efficacy of ICI.
	•PD-1 and CD69 expressed in CD8+ Tem from blood can predict TLS presence in the CRC macroenvironment.

Keywords

colorectal cancer / single-cell omics / spatial transcription / tumour macroenvironment

References

[1] SiegelRL, Giaquinto AN, JemalA. Cancer statistics, 2024. CA Cancer J Clin. 2024; 74(1): 12-49.

[2] FilipS, Vymetalkova V, PeteraJ, et al. Distant metastasis in colorectal cancer patients—do we have new predicting clinicopathological and molecular biomarkers?. A Comprehensive Review. Int J Mol Sci. 2020; 21(15): 5255.

[3] KishikiT, LapinB, MatsuokaH, et al. Optimal surveillance protocols after curative resection in patients with stage IV colorectal cancer: a multicenter retrospective study. Dis Colon Rectum. 2018; 61(1): 51-57.

[4] TsikitisVL, Malireddy K, GreenEA, et al. Postoperative surveillance recommendations for early stage colon cancer based on results from the clinical outcomes of surgical therapy trial. J Clin Oncol. 2009; 27(22): 3671-3676.

[5] CercekA, LumishM, SinopoliJ, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med. 2022; 386(25): 2363-2376.

[6] HuH, KangL, ZhangJ, et al. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2022; 7(1): 38-48.

[7] LeDT, UramJN, WangH, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015; 372(26): 2509-2520.

[8] LeDT, DurhamJN, SmithKN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017; 357(6349): 409-413.

[9] SinicropeFA. Lynch syndrome-associated colorectal cancer. N Engl J Med. 2018; 379(8): 764-773.

[10] GrossmanJE, Vasudevan D, JoyceCE, HildagoM. Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor. Oncogene. 2021; 40(8): 1393-1395.

[11] KangYK, BokuN, SatohT, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (Lond, Engl). 2017; 390(10111): 2461-2471.

[12] JungJ, HeoYJ, ParkS. High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis. J Immunother Cancer. 2023; 11(4): e006454.

[13] HellmannMD, Ciuleanu TE, PluzanskiA, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018; 378(22): 2093-2104.

[14] CristescuR, Aurora-Garg D, AlbrightA, et al. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors. J Immunother Cancer. 2022; 10(1): e003091.

[15] ZhangL, LiZ, SkrzypczynskaKM, et al. Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer. Cell. 2020; 181(2): 442-459. e29.

[16] LeeHO, HongY, EtliogluHE, et al. Lineage-dependent gene expression programs influence the immune landscape of colorectal cancer. Nat Genet. 2020; 52(6): 594-603.

[17] ZengD, WuJ, LuoH, et al. Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer. J Immunother Cancer. 2021; 9(8): e002467.

[18] YostKE, ChangHY, SatpathyAT. Recruiting T cells in cancer immunotherapy. Science. 2021; 372(6538): 130-131.

[19] AllenBM, HiamKJ, BurnettCE, et al. Systemic dysfunction and plasticity of the immune macroenvironment in cancer models. Nat Med. 2020; 26(7): 1125-1134.

[20] SteeleNG, Carpenter ES, KempSB, et al. Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancer. Nat Cancer. 2020; 1(11): 1097-1112.

[21] KumarV, PatelS, TcyganovE, Gabrilovich DI. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 2016; 37(3): 208-220.

[22] PorporatoPE. Understanding cachexia as a cancer metabolism syndrome. Oncogenesis. 2016; 5(2): e200.

[23] RanGH, LinYQ, TianL, et al. Natural killer cell homing and trafficking in tissues and tumors: from biology to application. Signal Transduc Target Ther. 2022; 7(1): 205.

[24] OginoS, NoshoK, IraharaN, et al. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res. 2009; 15(20): 6412-6420.

[25] LewisSM, Asselin-Labat ML, NguyenQ, et al. Spatial omics and multiplexed imaging to explore cancer biology. Nat Methods. 2021; 18(9): 997-1012.

[26] ShinSM, Hernandez A, CoyneE, et al. CyTOF protocol for immune monitoring of solid tumors from mouse models. STAR Protocols. 2022; 4(1): 101949.

[27] JoanitoI, Wirapati P, ZhaoN, et al. Single-cell and bulk transcriptome sequencing identifies two epithelial tumor cell states and refines the consensus molecular classification of colorectal cancer. Nat Genet. 2022; 54(7): 963-975.

[28] MosesL, Pachter L. Museum of spatial transcriptomics. Nat Methods. 2022; 19(5): 534-546.

[29] QiJ, SunH, ZhangY, et al. Single-cell and spatial analysis reveal interaction of FAP(+) fibroblasts and SPP1(+) macrophages in colorectal cancer. Nat Commun. 2022; 13(1): 1742.

[30] FentonTM, Jørgensen PB, NissK, et al. Immune profiling of human gut-associated lymphoid tissue identifies a role for isolated lymphoid follicles in priming of region-specific immunity. Immunity. 2020; 52(3): 557-570. e6.

[31] FinckR, Simonds EF, JagerA, et al. Normalization of mass cytometry data with bead standards. Cytometry Part A. 2013; 83(5): 483-494.

[32] ChevrierS, Crowell HL, ZanotelliVRT, EnglerS, Robinson MD, BodenmillerB. Compensation of signal spillover in suspension and imaging mass cytometry. Cell Syst. 2018; 6(5): 612-620. e5.

[33] Van GassenS, Gaudilliere B, AngstMS, SaeysY, Aghaeepour N. CytoNorm: a normalization algorithm for cytometry data. Cytometry Part A. 2020; 97(3): 268-278.

[34] PedersenCB, DamSH, BarnkobMB, et al. cyCombine allows for robust integration of single-cell cytometry datasets within and across technologies. Nat Commun. 2022; 13(1): 1698.

[35] SmillieCS, BitonM, Ordovas-MontanesJ, et al. Intra-and inter-cellular rewiring of the human colon during ulcerative colitis. Cell. 2019; 178(3): 714-730. e22.

[36] QuintelierK, Couckuyt A, EmmaneelA, AertsJ, SaeysY, Van GassenS. Analyzing high-dimensional cytometry data using FlowSOM. Nat Protoc. 2021; 16(8): 3775-3801.

[37] WeberLM, Robinson MD. Comparison of clustering methods for high-dimensional single-cell flow and mass cytometry data. Cytometry Part A. 2016; 89(12): 1084-1096.

[38] DigginsKE, Greenplate AR, LeelatianN, WogslandCE, IrishJM. Characterizing cell subsets using marker enrichment modeling. Nat Methods. 2017; 14(3): 275-278.

[39] BlackS, Phillips D, HickeyJW, et al. CODEX multiplexed tissue imaging with DNA-conjugated antibodies. Nat Protoc. 2021; 16(8): 3802-3835.

[40] YoungMD, Behjati S. SoupX removes ambient RNA contamination from droplet-based single-cell RNA sequencing data. GigaScience. 2020; 9(12): giaa151.

[41] WolockSL, LopezR, KleinAM. Scrublet: computational identification of cell doublets in single-cell transcriptomic data. Cell Syst. 2019; 8(4): 281-291. e9.

[42] JinS, Guerrero-Juarez CF, ZhangL, et al. Inference and analysis of cell-cell communication using CellChat. Nat Commun. 2021; 12(1): 1088.

[43] KleshchevnikovV, Shmatko A, DannE, et al. Cell2location maps fine-grained cell types in spatial transcriptomics. Nat Biotechnol. 2022; 40(5): 661-671.

[44] GaoF, WangW, TanM, et al. DeepCC: a novel deep learning-based framework for cancer molecular subtype classification. Oncogenesis. 2019; 8(9): 44.

[45] EidePW, BruunJ, LotheRA, Sveen A. CMScaller: an R package for consensus molecular subtyping of colorectal cancer pre-clinical models. Sci Rep. 2017; 7(1): 16618.

[46] GuinneyJ, Dienstmann R, WangX, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015; 21(11): 1350-1356.

[47] PuntschartA, WeyE, JostarndtK, et al. Expression of fos and jun genes in human skeletal muscle after exercise. Am J Physiol. 1998; 274(1): C129-C137.

[48] ConsortiumH. The human body at cellular resolution: the NIH Human Biomolecular Atlas Program. Nature. 2019; 574(7777): 187-192.

[49] LiangF, Rezapour A, SzeponikL, et al. Antigen presenting cells from tumor and colon of colorectal cancer patients are distinct in activation and functional status, but comparably responsive to activated T cells. Cancers. 2021; 13(20): 5247.

[50] DuhenT, DuhenR, MontlerR, et al. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. Nat Commun. 2018; 9(1): 2724.

[51] SimoniY, BechtE, FehlingsM, et al. Bystander CD8(+) T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature. 2018; 557(7706): 575-579.

[52] HayashiY, MakinoT, SatoE, et al. Density and maturity of peritumoral tertiary lymphoid structures in oesophageal squamous cell carcinoma predicts patient survival and response to immune checkpoint inhibitors. Br J Cancer. 2023; 128(12): 2175-2185.

[53] VanherseckeL, BrunetM, GuéganJP, et al. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nat Cancer. 2021; 2(8): 794-802.

[54] LiJ, WuC, HuH, et al. Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer. Cancer Cell. 2023; 41(6): 1152-1169. e7.

[55] ReschkeR, Shapiro JW, YuJ, et al. Checkpoint blockade-induced dermatitis and colitis are dominated by tissue-resident memory T cells and Th1/Tc1 cytokines. Cancer Immunol Res. 2022; 10(10): 1167-1174.

[56] HugoW, Zaretsky JM, SunL, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016; 165(1): 35-44.

[57] HarsheRP, XieA, VuerichM, et al. Endogenous antisense RNA curbs CD39 expression in Crohn’s disease. Nat Commun. 2020; 11(1): 5894.

[58] LeeCH, KimMS. Macrophages keep your gut moving. Mol Cells. 2023; 46(11): 672-674.

[59] ViolaMF, Chavero-Pieres M, ModaveE, et al. Dedicated macrophages organize and maintain the enteric nervous system. Nature. 2023; 618(7966): 818-826.

[60] de VriesNL, van Unen V, IjsselsteijnME, et al. High-dimensional cytometric analysis of colorectal cancer reveals novel mediators of antitumour immunity. Gut. 2020; 69(4): 691-703.

[61] AllardB, LonghiMS, RobsonSC, Stagg J. The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets. Immunol Rev. 2017; 276(1): 121-144.

[62] LiberaJ, Wittner M, KantowskiM, et al. Decreased frequency of intestinal CD39(+) γδ(+) T cells with tissue-resident memory phenotype in inflammatory bowel disease. Front Immunol. 2020; 11: 567472.

[63] ChenB, Scurrah CR, McKinleyET, et al. Differential pre-malignant programs and microenvironment chart distinct paths to malignancy in human colorectal polyps. Cell. 2021; 184(26): 6262-6280. e26.

[64] KlementJD, Paschall AV, ReddPS, et al. An osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion. J Clin Invest. 2018; 128(12): 5549-5560.

[65] WuY, YangS, MaJ, et al. Spatiotemporal immune landscape of colorectal cancer liver metastasis at single-cell level. Cancer Discov. 2022; 12(1): 134-153.

[66] ChenT, ChenX, ZhangS, et al. The genome sequence archive family: toward explosive data growth and diverse data types. Genom Proteom Bioinform. 2021; 19(4): 578-583.

[67] CNCB-NGDC Members and Partners. Database resources of the National Genomics Data Center, China National Center for Bioinformation in 2024. Nucleic Acids Res. 2024; 52(D1): D18-D32.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.